Canaccord raised the firm’s price target on Privia Health (PRVA) to $30 from $29 and keeps a Buy rating on the shares. The firm said management’s mantra throughout its 4Q call its prudent execution of its business model and control over its financials (working cap management), prudent manner in building its value-based book and taking risk, and prudent actions in setting guidance and managing expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health Group’s Strong Performance and Promising Outlook Justifies Buy Rating
- Privia Health Group Reports Strong 2024 Financial Results
- Privia Health’s 2024 Earnings Call Highlights Growth
- Privia Health Group: Strong Financial Performance and Promising Growth Outlook Justify Buy Rating
- Privia Health Group: Strong Financial Performance and Strategic Positioning Drive Buy Rating